{"groups":[{"description":"Participants received tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.\n\nChemotherapy options were a platinum agent (cisplatin 60-80 mg/m² intravenously on Day 1 or oxaliplatin 130 mg/m² intravenously on Day 1) combined with a fluoropyrimidine (fluorouracil \\[750-800 mg/m² intravenously on Days 1-5\\] or capecitabine \\[1000 mg/m² orally twice daily on Days 1-14\\]) or paclitaxel (175 mg/m² intravenously on Day 1).","id":"FG000","title":"Tislelizumab + Chemotherapy"},{"description":"Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.\n\nChemotherapy options were a platinum agent (cisplatin 60-80 mg/m² intravenously on Day 1 or oxaliplatin 130 mg/m² intravenously on Day 1) combined with a fluoropyrimidine (fluorouracil \\[750-800 mg/m² intravenously on Days 1-5\\] or capecitabine \\[1000 mg/m² orally twice daily on Days 1-14\\]) or paclitaxel (175 mg/m² intravenously on Day 1).","id":"FG001","title":"Placebo + Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"252"},{"groupId":"FG001","numSubjects":"268"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"28"}],"type":"Sponsor Ended Study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"326"},{"groupId":"FG001","numSubjects":"323"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"324"},{"groupId":"FG001","numSubjects":"321"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"326"},{"groupId":"FG001","numSubjects":"323"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were randomly assigned (1:1), using an interactive response technology system, to either tislelizumab plus investigator-chosen chemotherapy or placebo plus investigator-chosen chemotherapy.\n\nRandomization was stratified by investigator-chosen chemotherapy (platinum plus fluoropyrimidine vs platinum plus paclitaxel), region (Asia \\[excluding Japan\\] vs Japan vs other regions), and previous definitive therapy (yes vs no).","recruitmentDetails":"This study was conducted at 162 centers in 16 countries/regions across Asia, Europe, North America, and Oceania."}